| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2022 | 179.19% | Chardan Capital | $65 → $55 | Maintains | Buy |
| 09/12/2022 | 47.21% | Cowen & Co. | $30 → $29 | Maintains | Market Perform |
| 05/04/2022 | 92.89% | Wells Fargo | $46 → $38 | Maintains | Equal-Weight |
| 04/29/2022 | 229.95% | Chardan Capital | $75 → $65 | Maintains | Buy |
| 03/10/2022 | 103.05% | Wells Fargo | $37 → $40 | Maintains | Equal-Weight |
| 11/10/2021 | 280.71% | Chardan Capital | $92 → $75 | Maintains | Buy |
| 11/08/2021 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/05/2021 | — | Argus Research | Downgrades | Buy → Hold | |
| 04/30/2021 | 367.01% | Chardan Capital | $112 → $92 | Maintains | Buy |
| 04/07/2021 | 661.42% | Benchmark | → $150 | Initiates Coverage On | → Buy |
| 02/24/2021 | 468.53% | Chardan Capital | → $112 | Upgrades | Neutral → Buy |
| 02/19/2021 | 468.53% | Chardan Capital | → $112 | Downgrades | Buy → Neutral |
| 01/08/2021 | — | Wells Fargo | Downgrades | Overweight → Equal-Weight | |
| 07/31/2020 | 468.53% | Chardan Capital | $86 → $112 | Maintains | Buy |
| 07/17/2020 | 458.38% | Cantor Fitzgerald | $85 → $110 | Maintains | Overweight |
| 06/08/2020 | 331.47% | Cantor Fitzgerald | $86 → $85 | Maintains | Overweight |
| 05/06/2020 | 356.85% | Argus Research | $67 → $90 | Maintains | Buy |
| 05/01/2020 | 336.55% | Cantor Fitzgerald | $75 → $86 | Maintains | Overweight |
| 05/01/2020 | 336.55% | Chardan Capital | $71 → $86 | Maintains | Buy |
| 04/30/2020 | 331.47% | Wells Fargo | $75 → $85 | Maintains | Overweight |
| 02/25/2020 | 280.71% | Wells Fargo | $66 → $75 | Maintains | Overweight |
| 09/12/2019 | 229.95% | Guggenheim | → $65 | Initiates Coverage On | → Buy |
| 09/04/2019 | 224.87% | Wells Fargo | $61 → $64 | Upgrades | Market Perform → Outperform |
| 11/02/2018 | 280.71% | Cantor Fitzgerald | $68 → $75 | Maintains | Overweight |
| 11/02/2018 | 280.71% | Goldman Sachs | $60 → $75 | Upgrades | Neutral → Buy |
| 09/04/2018 | 235.03% | Chardan Capital | $60 → $66 | Maintains | Buy |
| 08/30/2018 | 229.95% | Wells Fargo | $61 → $65 | Maintains | Market Perform |
| 06/13/2018 | 214.72% | Argus Research | → $62 | Initiates Coverage On | → Buy |
| 06/12/2018 | 214.72% | Cantor Fitzgerald | → $62 | Initiates Coverage On | → Overweight |
| 04/25/2018 | — | Wells Fargo | Downgrades | Outperform → Market Perform | |
| 02/27/2018 | 204.57% | Singular Research | $45 → $60 | Maintains | Buy |
| 01/24/2018 | 179.19% | Goldman Sachs | → $55 | Initiates Coverage On | → Neutral |
Emergent BioSolutions Questions & Answers
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Chardan Capital on November 9, 2022. The analyst firm set a price target for $55.00 expecting EBS to rise to within 12 months (a possible 179.19% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Emergent BioSolutions (NYSE: EBS) was provided by Chardan Capital, and Emergent BioSolutions maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Emergent BioSolutions, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Emergent BioSolutions was filed on November 9, 2022 so you should expect the next rating to be made available sometime around November 9, 2023.
While ratings are subjective and will change, the latest Emergent BioSolutions (EBS) rating was a maintained with a price target of $65.00 to $55.00. The current price Emergent BioSolutions (EBS) is trading at is $19.70, which is out of the analyst's predicted range.